Stock Events

Stock Events

Addex Therapeutics 

$3.65
13
-$0.06-1.62% Friday 19:53
-$0.10-2.74%Friday 20:32After hours

Statistics

Day High
3.65
Day Low
3.65
52W High
12.05
52W Low
3.4
Volume
1,081
Avg. Volume
-
Mkt Cap
4.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q3 2024
Q1 2025
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.03
-0.02
-0.01
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-21,994.18%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
37,672.35Revenue
-8.29MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADXN. It's not an investment recommendation.
Apple
2
AAPL
Amazon
2
AMZN
NVIDIA
2
NVDA
AMD
2
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes plc operates in the CNS therapeutic area, making it a direct competitor to Addex Therapeutics in developing treatments for neurological disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
ACADIA Pharmaceuticals specializes in CNS disorders, including Parkinson’s disease psychosis, directly competing with Addex's focus areas.
BridgeBio Pharma
BBIO
Mkt Cap14.97B
BridgeBio Pharma targets genetic diseases and cancers, including neurological disorders, overlapping with Addex Therapeutics' research focus.
Biogen
BIIB
Mkt Cap32.28B
Biogen is a major player in neurodegenerative diseases, Alzheimer's, and multiple sclerosis, competing in the CNS space.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's broad focus on innovative therapeutics includes CNS disorders, positioning it as a competitor in the neurological space.
Palatin Technologies
PTN
Mkt Cap18.65M
Palatin Technologies works on developing therapeutics for diseases with a focus on CNS, making it a competitor in the neurological treatment market.
Novartis
NVS
Mkt Cap292.35B
Novartis has a diversified portfolio that includes treatments for neurological conditions, competing with Addex in the broader CNS therapeutic area.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a wide range of therapeutic areas, including CNS disorders, making it a competitor in developing treatments for neurological conditions.

About

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Show more...
CEO
Timothy Mark Dyer
Employees
3
Country
Switzerland
ISIN
US00654J2069
WKN
000A3EXC6

Listings

MU
DE
APE.MU
STU
DE
APE1.STU
MU
DE
APE0.MU
LSE
GB
0QNV.LSE

0 Comments

Share your thoughts

FAQ

What is Addex Therapeutics stock price today?▼
The current price of ADXN is $3.65 USD — it has decreased by -1.62% in the past 24 hours. Watch Addex Therapeutics stock price performance more closely on the chart.
What is Addex Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Addex Therapeutics stocks are traded under the ticker ADXN.
Is Addex Therapeutics stock price growing?▼
ADXN stock has fallen by -4.95% compared to the previous week, the month change is a -37.07% fall, over the last year Addex Therapeutics has showed a -54.94% decrease.
What is Addex Therapeutics market cap?▼
Today Addex Therapeutics has the market capitalization of 4.62M
When is the next Addex Therapeutics earnings date?▼
Addex Therapeutics is going to release the next earnings report on November 09, 2026.
What were Addex Therapeutics earnings last quarter?▼
ADXN earnings for the last quarter are -0.01 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Addex Therapeutics revenue for the last year?▼
Addex Therapeutics revenue for the last year amounts to 37,672.35 USD.
What is Addex Therapeutics net income for the last year?▼
ADXN net income for the last year is -8.29M USD.
How many employees does Addex Therapeutics have?▼
As of September 06, 2026, the company has 3 employees.
In which sector is Addex Therapeutics located?▼
Addex Therapeutics operates in the Health & Wellness sector.
When did Addex Therapeutics complete a stock split?▼
The last stock split for Addex Therapeutics was on October 23, 2023 with a ratio of 1:20.
Where is Addex Therapeutics headquartered?▼
Addex Therapeutics is headquartered in Geneva, Switzerland.